ImmunityBio Inc (NASDAQ:IBRX) saw a downside of -0.30% to $1.64 after subtracting -$0.01 on Monday. The 5-day average trading volume is 1,983,721 shares of the company’s common stock. It has gained $1.8000 in the past week and touched a new high 1 time within the past 5 days. An average of 3,320,425 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,845,244.
IBRX’s 1-month performance is 2.81% or $0.0050 on its low of $1.2700 reached on 09/08/23. The company’s shares have touched a 52-week low of $1.21 and high of $7.10, with the stock’s rally to the 52-week high happening on 05/09/23. YTD, IBRX has lost -67.55% or -$3.4150 and has reached a new high 4 times. However, the current price is down -76.83% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
IBRX stock has a beta of 1.37. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1272.09.
ImmunityBio Inc’s quick ratio for the period ended June 29 was 0.11, with the current ratio over the same period at 0.11. In terms of profitability, the gross margin trailing 12 months is -4198.82%. The trailing 12-month EBITDA margin is -136010.42% while for the period ending June 29, ImmunityBio Inc’s operating margin was -62795.27%. The firm’s gross profit as reported stood at $351.54 million against revenue of $0.24 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 31.4% to -$137.88 million, while revenue of -$116.34 million was 15.62% off the previous quarter. Analysts expected IBRX to announce -$0.23 per share in earnings in its latest quarter, but it posted -$0.32, representing a -39.10% surprise. EBITDA for the quarter stood at more than -$68.17 million. IBRX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 936.41 million, with total debt at $819.26 million. Shareholders hold equity totaling $456.25 million.
Let’s look briefly at ImmunityBio Inc (IBRX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 September was 49.90% to suggest the stock is trending Neutral, with historical volatility in this time period at 121.35%.
The stock’s 5-day moving average is $1.6810, reflecting a -0.90% or -$0.0150 change from its current price. IBRX is currently trading +0.30% above its 20-day SMA, -46.27% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -40.47% and SMA200 by-70.86%.
Stochastic %K and %D was 64.94% and 68.39% and the average true range (ATR) pointed at 0.1474. The RSI (14) points at 47.31%, while the 14-day stochastic is at 66.38% with the period’s ATR at 0.1537. The stock’s 9-day MACD Oscillator is pointing at -0.0428 and 0.0413 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for ImmunityBio Inc (NASDAQ: IBRX), Piper Sandler downgraded it to a Neutral rating. They previously had an Overweight rating on the stock.
What is IBRX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $5.00 and a high of $5.00, with their median price target at $5.00. Looking at these predictions, the average price target given by analysts is for ImmunityBio Inc (IBRX) stock is $5.00.
